Padoprazan - Ildong Pharmaceutical
Alternative Names: ID-120040002Latest Information Update: 19 Mar 2025
At a glance
- Originator Ildong Pharmaceutical
- Class Antiulcers; Polyclonal antibodies
- Mechanism of Action Potassium-competitive acid blockers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Gastro-oesophageal reflux
Most Recent Events
- 19 Mar 2025 Phase-II clinical trials in Gastro-oesophageal reflux in South Korea (unspecified route) Prior to March 2025 (Yuvonia Pipeline, March 2025)
- 22 Jun 2024 Yunovia and Daewon Pharmaceutical enters into co-development and licensing agreement for ‘P-CAB’
- 22 Jun 2024 Yunovia has patent pending application for padoprazan in South Korea, the US, Japan, and Australia to secure the new drug substance rights (Prior to June 2024)